Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N. Hashimoto J, et al. Among authors: van der heijde d. Mod Rheumatol. 2009;19(3):273-82. doi: 10.1007/s10165-009-0170-4. Epub 2009 May 19. Mod Rheumatol. 2009. PMID: 19452245 Clinical Trial.
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Garnero P, Landewé R, Boers M, Verhoeven A, Van Der Linden S, Christgau S, Van Der Heijde D, Boonen A, Geusens P. Garnero P, et al. Among authors: van der heijde d, van der linden s. Arthritis Rheum. 2002 Nov;46(11):2847-56. doi: 10.1002/art.10616. Arthritis Rheum. 2002. PMID: 12428224 Free article. Clinical Trial.
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Landewé R, Geusens P, Boers M, van der Heijde D, Lems W, te Koppele J, van der Linden S, Garnero P. Landewé R, et al. Among authors: van der heijde d, van der linden s. Arthritis Rheum. 2004 May;50(5):1390-9. doi: 10.1002/art.20222. Arthritis Rheum. 2004. PMID: 15146408 Free article. Clinical Trial.
Radiographic progression in rheumatoid arthritis.
Landewé R, van der Heijde D. Landewé R, et al. Among authors: van der heijde d. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S63-8. Clin Exp Rheumatol. 2005. PMID: 16273787
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.
Keeling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP. Keeling SO, et al. Among authors: van der heijde d. J Rheumatol. 2007 Mar;34(3):623-33. J Rheumatol. 2007. PMID: 17343310 Review.
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
Maksymowych WP, Landewe R, Boers M, Garnero P, Geusens P, El-Gabalawy H, Heinegard D, Kraus VB, Lohmander S, Matyas J, Saxne T, van der Heijde D. Maksymowych WP, et al. Among authors: van der heijde d. J Rheumatol. 2007 Mar;34(3):634-40. J Rheumatol. 2007. PMID: 17343311
1,113 results